Non-adherence is a serious financial concern. John Hosken of Eye for Pharma estimates that
"...drug companies are losing around 25 billlion euros each year simply through patients not taking their medicine."With such high stakes, patient groups could be an asset to industry's toolbox.
(Source: Report from Patient Compliance Europe Conference, hosted by Eye for Pharma in 2006)